Studiul urmareste evaluarea eficacitatii si sigurantei administrarii de MK-7625A (ceftolozane/tazobactam) comparativ cu meropenem la pacientii pediatrici cu infectie urinara complicata, inclusiv pielonefrita.

Titlu Studiu

A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including Pyelonephritis

Cod protocol: MK-7625A-034

Numar EudraCT: 2016-004153-32

Sponsor: Merck Sharp & Dohme Corp.

Medicament de investigatie clinica: MK-7625A

Medicament de investigatie clinica comparator: Meropenem

Placebo: Nu

International/National: international

Faza: II